Defensins: A novel weapon against Mycobacterium tuberculosis ?
Xuehan Gao,Jihong Feng,Linna Wei,Pinzhi Dong,Jin Chen,Langlang Zhang,Yuhan Yang,Lin Xu,Haiyan Wang,Junmin Luo,Ming Qin
DOI: https://doi.org/10.1016/j.intimp.2023.111383
IF: 5.714
2023-12-22
International Immunopharmacology
Abstract:Tuberculosis (TB) is a serious airborne communicable disease caused by organisms of the Mycobacterium tuberculosis ( Mtb ) complex. Although the standard treatment antimicrobials, including isoniazid, rifampicin, pyrazinamide, and ethambutol, have made great progress in the treatment of TB, problems including the rising incidence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), the severe toxicity and side effects of antimicrobials, and the low immunity of TB patients have become the bottlenecks of the current TB treatments. Therefore, both safe and effective new strategies to prevent and treat TB have become a top priority. As a subfamily of cationic antimicrobial peptides, defensins are rich in cysteine and play a vital role in resisting the invasion of microorganisms and regulating the immune response. Inspired by studies on the roles of defensins in host defence, we describe their research history and then review their structural features and antimicrobial mechanisms, specifically for fighting Mtb in detail. Finally, we discuss the clinical relevance, therapeutic potential, and potential challenges of defensins in anti-TB therapy. We further debate the possible solutions of the current application of defensins to provide new insights for eliminating Mtb .
pharmacology & pharmacy,immunology